Derivation of a triple mosaic adenovirus for cancer gene therapy.

A first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapy. PLoS One (2012) 0.86

Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis (2014) 0.84

Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model. J Mol Biochem (2012) 0.76

Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes. PLoS One (2014) 0.76

A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth. Oncotarget (2015) 0.75

A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol (2004) 10.60

The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology (1968) 7.42

Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol (2001) 4.25

Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69

Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A (2000) 3.24

Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med (1997) 2.67

Gene therapy clinical trials worldwide to 2007--an update. J Gene Med (2007) 2.56

The cleavage activities of aphthovirus and cardiovirus 2A proteins. J Gen Virol (1997) 1.82

Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med (2004) 1.79

Cell-free human immunodeficiency virus type 1 transcytosis through primary genital epithelial cells. J Virol (2006) 1.74

AAV transcytosis through barrier epithelia and endothelium. Mol Ther (2005) 1.60

Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther (2007) 1.48

Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35

CryoEM structure at 9A resolution of an adenovirus vector targeted to hematopoietic cells. J Mol Biol (2005) 1.35

Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther (2006) 1.34

Use of adenovirus protein IX (pIX) to display large polypeptides on the virion--generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther (2004) 1.21

Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19

Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18

Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther (2004) 1.15

Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging (2006) 1.13

Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst (2006) 1.10

Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J Virol (2004) 1.08

The subgenus-specific C-terminal region of protein IX is located on the surface of the adenovirus capsid. J Virol (1999) 1.05

Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology (2005) 1.03

Cancer gene therapy: scientific basis. Annu Rev Med (2002) 0.98

Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology (2008) 0.95

Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. Virology (2004) 0.94

A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology (2003) 0.91

Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model. Gene Ther (2006) 0.88

A mosaic fiber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fibers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin Cancer Res (2007) 0.87

Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control. J Gene Med (2006) 0.86

In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection. J Mol Biol (2009) 0.86

Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J Gen Virol (2005) 0.85

Fiber-mosaic adenovirus as a novel approach to design genetically modified adenoviral vectors. Virus Res (2004) 0.82

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35

Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77

Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69

Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56

Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13

MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90

Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88

Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86

A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86

Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74

Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66

Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Nanomedicine (2005) 1.66

mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61

Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett (2006) 1.61

mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55

OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52

Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48

Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48

A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43

Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene (2005) 1.43

Focal adhesion kinase (FAK)-related non-kinase inhibits myofibroblast differentiation through differential MAPK activation in a FAK-dependent manner. J Biol Chem (2008) 1.42

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41

Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39

Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35

Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35

mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34

Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol (2002) 1.33

Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31

Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res (2007) 1.31

Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30

mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28

Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 1.28

Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology (2004) 1.27

Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther (2009) 1.25

PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23

Structure and uncoating of immature adenovirus. J Mol Biol (2009) 1.23

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21

A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21

Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19

Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19

Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18

Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18

Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18

Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18

MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18

The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res (2002) 1.17

Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15

Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther (2009) 1.14

Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol (2008) 1.14

Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14

Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14

Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res (2002) 1.13

Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging (2006) 1.13

Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol (2007) 1.13

Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol (2008) 1.13

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12

Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12

Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12

Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12

Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther (2008) 1.11

Scavenger receptor A: a new route for adenovirus 5. Mol Pharm (2009) 1.10

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10

A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. J Biol Chem (2006) 1.10

Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst (2006) 1.10

Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther (2004) 1.10

Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res (2006) 1.09

MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther (2009) 1.08

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 1.08

Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines (2009) 1.08

Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res (2007) 1.07

HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One (2010) 1.07

Localization of the N-terminus of minor coat protein IIIa in the adenovirus capsid. J Mol Biol (2008) 1.06

PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy (2008) 1.06

Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology (2002) 1.06

Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Mol Pharmacol (2009) 1.06

Genetic targeting strategies for adenovirus. Mol Pharm (2005) 1.05

Isolation of embryonic stem-like cells from equine blastocysts and their differentiation in vitro. FEBS Lett (2002) 1.05

Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther (2010) 1.04

Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol (2002) 1.04

A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res (2012) 1.04

FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol (2013) 1.04

OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biol Ther (2010) 1.03

Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology (2005) 1.03

Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J (2008) 1.03

Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol (2003) 1.02

An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology (2004) 1.02

Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther (2010) 1.02